CompletedNot Applicable

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

Japan63 participantsStarted 2014-09-02

Plain-language summary

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female participants with a confirmed diagnosis of Gaucher disease * Participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for Gaucher disease * Participants who start VPRIV treatment or transition from VPRIV clinical studies during the enrollment period Exclusion Criteria: \-

What they're measuring

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE) Following Initiation of Treatment With Velaglucerase Alfa

Timeframe: Baseline up to end of the study (8 years)

Trial details

NCT IDNCT03625882

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-05-14

Results submitted2024-11-11

View on ClinicalTrials.gov More Gaucher Disease trials